This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie (ABBV) Skyrizi Gets CHMP Nod for Ulcerative Colitis in EU
by Zacks Equity Research
AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.
Ultragenyx (RARE) DTX401 Meets Goals in Metabolic Disorder Study
by Zacks Equity Research
Ultragenyx (RARE) reports meeting primary and secondary endpoints in the late-stage study of its investigational gene therapy, DTX401, to treat glycogen storage disease type Ia.
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
by Zacks Equity Research
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
Prothena (PRTA), Bristol Myers Tie Up for Second Neuro Candidate
by Zacks Equity Research
Prothena (PRTA) announces that Bristol Myers is exercising its option for the second time, thereby in-licensing exclusive global rights for PRX019 to potentially treat neurodegenerative diseases.
Candel (CADL) Stock Skyrockets 431% Year to Date: Here's Why
by Zacks Equity Research
Candel (CADL) surges 431% in the year-to-date period, driven by positive developmental and regulatory updates from the clinical program for CAN-2409 across two different cancer indications.
Wall Street Analysts Think Annovis Bio (ANVS) Could Surge 359.53%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Annovis Bio (ANVS) points to a 359.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Apellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
by Zacks Equity Research
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
by Zacks Equity Research
Verastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line patients treated with novel combo therapy in the initial cohort of its phase I/II pancreatic cancer study.
Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M
by Zacks Equity Research
Bicycle Therapeutics (BCYC) gains 10% upon entering a PIPE financing agreement with multiple institutional investors, which is expected to generate gross proceeds of $555 million.
Deciphera's (DCPH) Shares Surge 74.3% in a Month: Here's Why
by Zacks Equity Research
Deciphera (DCPH) soars 74.3% in the past month on a $2.4 billion buy-out offer from ONO Pharmaceuticals. The transaction is expected to close in the third quarter of 2024.
Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why
by Zacks Equity Research
Krystal Biotech (KRYS) soars 36.5% on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
Dr. Reddy's (RDY), Alvotech Unite for Prolia & Xgeva Biosimilar
by Zacks Equity Research
Dr. Reddy's (RDY) announces entering into a license and supply agreement with Alvotech to develop and commercialize the latter's biosimilar candidate, AVT03, to Prolia and Xgeva.
PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug
by Zacks Equity Research
PTC Therapeutics (PTCT) gains 21% on May 20 after the EC decided against adopting the negative CHMP opinion of January 2024 on the annual renewal of the conditional approval of Translarna.
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
by Zacks Equity Research
Beigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology drugs, Tevimbra, to treat three NSCLC indications, including first- and second-line use, in the EU.
Eli Lilly's (LLY) Efsitora Matches Daily Insulins in A1C Control
by Zacks Equity Research
Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Amgen's (AMGN) Tarlatamab Receives FDA Approval for SCLC
by Zacks Equity Research
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
by Zacks Equity Research
Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
by Zacks Equity Research
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
by Zacks Equity Research
Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
Acadia (ACAD) Q1 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Acadia's (ACAD) earnings in the first quarter of 2024 beat the Zacks Consensus Estimate, while revenues miss the same.
Intra-Cellular (ITCI) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Intra-Cellular (ITCI) reports first-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
Pacira (PCRX) Q1 Earnings Miss, Exparel Sales Drive Revenues
by Zacks Equity Research
Pacira (PCRX) reports first-quarter 2024 results, wherein earnings miss but revenues beat estimates, driven by Exparel sales.
Apellis' (APLS) Q1 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.